Last Updated on February 20, 2023 by Anshima Gupta
Ottawa, Feb 18 (IANS) Health Canada announced that it has authorized the use of Moderna’s Spikevax bivalent Covid-19 booster vaccine for children and adolescents aged six to 17 years of age targeting the Omicron variant BA.1.
A booster dose of 50 micrograms may be administered in individuals 12 years of age and older at least 4 months after completing their primary vaccine series or a previous booster dose and a booster dose of 25 micrograms in children 6 to 11 years of age at least 6 months after completing their primary vaccine series or a previous booster dose, Xinhua news agency quoted the health body as saying.
“The authorization of a booster dose in children and adolescents is a critical step to broaden protection against the Omicron family of variants, and the emergence of new variants of concern in Canada,” said Stephane Bancel, chief executive officer of Moderna, in a news release.
The BA.1 booster was previously approved for people aged 18 and over.
Moderna’s Omicron-targeting bivalent booster for variant BA.4/5 has not yet been approved for use in people under 18 years of age.
Disclaimer: Medical Science is an ever evolving field. We strive to keep this page updated. In case you notice any discrepancy in the content, please inform us at [email protected]. You can futher read our Correction Policy here. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website or it's social media channels. Read our Full Disclaimer Here for further information.
